Title: 
Official Title: To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.
Number of Sections: 2
Source: versions - Introduced in Senate
Media Type: text/xml

================================================================================

Section 1:
1.Short titleThis Act may be cited as the Expedited Access to Biosimilars Act.

Section 2:
2.Assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy in clinical studies required for licensure of biological products as biosimilar(a)In generalSection 351(k)(2)(A) of the Public Health Service Act (42 U.S.C. 262(k)(2)(A)) is amended—(1)in clause (i)(I)—(A)in item (bb), by striking and at the end; and(B)by striking item (cc) and inserting the following(cc)a clinical study or studies assessing pharmacokinetics that are sufficient to demonstrate safety, purity, and potency; and(dd)subject to clause (iv), a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product;; and(2)by adding at the end the following:(iv)Clinical studies(I)In generalSubject to subclause (II), the Secretary may determine, in the Secretary's discretion, that a clinical study required under clause (i)(I)(dd) shall include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. (II)RequirementThe Secretary may only require the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy pursuant to a determination under subclause (I) if the Secretary provides to the applicant notice of the requirement, including a written justification of the basis for such determination, not later than the earliest date on which the applicant may file the application under this subsection..(b)ApplicabilityThe amendments made by subsection (a) shall apply with respect to an application submitted under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) on or after the date of enactment of this Act.


================================================================================

Raw Text:
119 S1414 IS: Expedited Access to Biosimilars Act
U.S. Senate
2025-04-10
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



II119th CONGRESS1st SessionS. 1414IN THE SENATE OF THE UNITED STATESApril 10, 2025Mr. Paul introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILLTo amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.1.Short titleThis Act may be cited as the Expedited Access to Biosimilars Act.2.Assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy in clinical studies required for licensure of biological products as biosimilar(a)In generalSection 351(k)(2)(A) of the Public Health Service Act (42 U.S.C. 262(k)(2)(A)) is amended—(1)in clause (i)(I)—(A)in item (bb), by striking and at the end; and(B)by striking item (cc) and inserting the following(cc)a clinical study or studies assessing pharmacokinetics that are sufficient to demonstrate safety, purity, and potency; and(dd)subject to clause (iv), a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product;; and(2)by adding at the end the following:(iv)Clinical studies(I)In generalSubject to subclause (II), the Secretary may determine, in the Secretary's discretion, that a clinical study required under clause (i)(I)(dd) shall include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. (II)RequirementThe Secretary may only require the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy pursuant to a determination under subclause (I) if the Secretary provides to the applicant notice of the requirement, including a written justification of the basis for such determination, not later than the earliest date on which the applicant may file the application under this subsection..(b)ApplicabilityThe amendments made by subsection (a) shall apply with respect to an application submitted under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) on or after the date of enactment of this Act.